Immune effector cells and antigen-presenting cells (IECs and APCs)

Immune effector cells and antigen-presenting cells (APCs) represent the functional cellular units of the immune system rather than a single molecular target. Immune effector cells, such as T lymphocytes and Natural Killer (NK) cells, are responsible for the direct elimination of pathogens and malignant cells through cytotoxic mechanisms (NCI Dictionary, 2024). Antigen-presenting cells, including dendritic cells, macrophages, and B cells, play a critical role in the initiation of the adaptive immune response by processing antigens and presenting them to T cells via Major Histocompatibility Complex (MHC) molecules (Janeway's Immunobiology, 2017). In the context of modern pharmacology, these cells are the primary focus of immunotherapies such as checkpoint inhibitors, which prevent the inactivation of effector cells, and CAR-T cell therapies, which involve the infusion of engineered effector cells (Nature Reviews Drug Discovery, 2020). Because this term describes a broad category of cell types with diverse molecular profiles, it is not classified as a specific therapeutic target like a receptor or enzyme. Instead, it serves as a conceptual framework for therapies that aim to harness or modulate the body's natural immune defenses to treat cancer, infections, and autoimmune disorders (StatPearls, 2023).

Other names

Immune cellsLeukocytesProfessional antigen-presenting cellsEffector lymphocytesImmune system components

Therapeutic strategies involve the modulation of these cells through checkpoint inhibition to restore effector function, the use of bispecific antibodies to bridge effector cells to targets, or the adoptive transfer of genetically modified cells to enhance specific immune recognition and destruction of pathological cells (Nature Reviews Drug Discovery, 2020).